REVIEW article
Front. Public Health
Sec. Public Health Policy
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1585180
This article is part of the Research TopicEthical and Legal Implications of Artificial Intelligence in Public Health: Balancing Innovation and PrivacyView all 11 articles
Exploring the Ethical Issues Posed by AI and Big Data Technologies in Drug Development
Provisionally accepted
- College of Pharmacy, Shanghai University of Medicine & Health Science, Shanghai, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The rapid development and wide application of Artificial Intelligence (AI) and Big Data technologies have profoundly changed the way industries around the world operate, from finance, transportation, education to media, the integration of the two not only improves the efficiency of the industry, but also optimizes the quality of service and decision-making process to a large extent. In the era of deep integration of Biomedicine and AI, AI and Big Data technology are reconstructing the paradigm of drug development with unprecedented intensity.The long cycle of traditional drug development, which takes a decade and billions of dollars in investment, is being compressed to two years or even less under the drive of AI.Through big data analytics and deep learning techniques, AI can greatly improve R&D efficiency and accuracy in a variety of aspects such as compound screening, efficacy prediction, and clinical (pre)experiment design. However, the use of AI and big data in drug discovery and development also raises corresponding ethical issues, such as data privacy protection and algorithmic transparency. This article will systematically analyze the technological breakthroughs, potential risks, and governance paths of AI and big data in drug development. It will explore how to strengthen the bottom -line of safety and ethics in the Efficiency Revolution and build a responsible innovation ecosystem.
Keywords: artificial intelligence, big data, Drug Development, ethical issues, Responsible innovation
Received: 28 Feb 2025; Accepted: 26 Aug 2025.
Copyright: © 2025 Fan, wang and wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yulu Fan, College of Pharmacy, Shanghai University of Medicine & Health Science, Shanghai, Shanghai, China
tizong wang, College of Pharmacy, Shanghai University of Medicine & Health Science, Shanghai, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.